Beyond Supportive Care: Mitochondria as a Strategic Therapeutic Avenue in Acute Pancreatitis.
Serge Chooklin, Serhii Chuklin · Digestive diseases and sciences · 2026
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
This narrative review examined to synthesize experimental and clinical evidence on mitochondria-targeted strategies in acute pancreatitis (AP) and evaluate the potential of interventions that preserve or restore mitochondrial function to reduce pancreatic injury and systemic complications. Redox modulation using Nrf2 activators (sulforaphane, paeonol, hydroxytyrosol, curcumin), MitoTEMPO, tiron, and hydrogen-rich saline reduced mtROS production and inflammasome activation, although MitoQ and SkQ1 showed mixed or adverse effects. However, evidence remains predominantly preclinical, heterogeneous, and limited by challenges in targeted delivery across the hemato-pancreatic barrier. The reviewed evidence adds support for molecular hydrogen's therapeutic potential across the conditions, mechanisms, or outcomes examined.
What the Findings Mean
H2HUBB reviewed this publication as a synthesis of molecular-hydrogen research and summarizes the outcomes emphasized by the authors. Redox modulation using Nrf2 activators (sulforaphane, paeonol, hydroxytyrosol, curcumin), MitoTEMPO, tiron, and hydrogen-rich saline reduced mtROS production and inflammasome activation, although MitoQ and SkQ1 showed mixed or adverse effects.
What the Researchers Studied
The authors reviewed to synthesize experimental and clinical evidence on mitochondria-targeted strategies in acute pancreatitis (AP) and evaluate the potential of interventions that preserve or restore mitochondrial function to reduce pancreatic injury and systemic complications.
What Effects Did Molecular Hydrogen Have?
Redox modulation using Nrf2 activators (sulforaphane, paeonol, hydroxytyrosol, curcumin), MitoTEMPO, tiron, and hydrogen-rich saline reduced mtROS production and inflammasome activation, although MitoQ and SkQ1 showed mixed or adverse effects. The authors concluded that however, evidence remains predominantly preclinical, heterogeneous, and limited by challenges in targeted delivery across the hemato-pancreatic barrier.
Why These Findings Matter
The reviewed evidence adds support for molecular hydrogen's therapeutic potential across the conditions, mechanisms, or outcomes examined.
How Strong Is This Evidence?
This is review or synthesis evidence (narrative review).
Technical Study Details
H2HUBB classifies this publication as narrative review with review or synthesis evidence. The study used a narrative review.
Limitations and Safety
Reported limitations: However, evidence remains predominantly preclinical, heterogeneous, and limited by challenges in targeted delivery across the hemato-pancreatic barrier.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.